Valuation: Eli Lilly and Company

Market Cap 1,263B 1,131B 1,040B 943B 1,762B 119,892B 1,795B 12,405B 4,980B 63,067B 4,739B 4,638B 198,889B P/E 2026 *
41.4x
P/E 2027 * 30x
Enterprise Value 1,286B 1,152B 1,060B 960B 1,795B 122,145B 1,828B 12,638B 5,073B 64,252B 4,828B 4,725B 202,626B EV / Sales 2026 *
14x
EV / Sales 2027 * 12.1x
Free-Float
99.9%
Yield 2026 *
0.48%
Yield 2027 * 0.54%
1 day+3.19%
1 week+11.31%
1 month+22.51%
3 months+23.39%
6 months+51.67%
Current year+31.90%
1 week 1,260.34
Extreme 1260.34
1,449.68
1 month 1,131.21
Extreme 1131.21
1,449.68
Current year 850.51
Extreme 850.51
1,449.68
1 year 850.51
Extreme 850.51
1,449.68
3 years 561.65
Extreme 561.65
1,449.68
5 years 231.87
Extreme 231.87
1,449.68
10 years 64.18
Extreme 64.18
1,449.68
Manager TitleAgeSince
Chief Executive Officer 58 2016-12-31
Director of Finance/CFO 49 2024-09-08
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 66 2004-12-31
Director/Board Member 70 2009-03-31
Director/Board Member 54 2011-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Free

Director

11 0.0000%
9/21/26 Free

Director

14 0.0000%
9/21/26 Free

Director

9 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
+2.21%+2.29%-15.78%-60.69% 176B
Average +2.10%+5.54%+40.35%+70.04% 443.77B
Weighted average by Cap. +2.01%+6.43%+47.88%+94.05%

Financials

2026 *2027 *
Net sales 91.65B 82.09B 75.51B 68.41B 128B 8,703B 130B 900B 361B 4,578B 344B 337B 14,437B 105B 93.89B 86.36B 78.25B 146B 9,954B 149B 1,030B 413B 5,236B 393B 385B 16,512B
Net income 30.77B 27.56B 25.35B 22.97B 42.93B 2,922B 43.74B 302B 121B 1,537B 115B 113B 4,847B 42.01B 37.62B 34.61B 31.36B 58.61B 3,989B 59.71B 413B 166B 2,098B 158B 154B 6,617B
Net Debt 23.73B 21.25B 19.55B 17.71B 33.11B 2,253B 33.73B 233B 93.57B 1,185B 89.05B 87.15B 3,737B 7.38B 6.61B 6.08B 5.51B 10.3B 701B 10.49B 72.54B 29.12B 369B 27.71B 27.12B 1,163B
Projected Income Statement - Annual - Eli Lilly and Company
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
26-10-30 US$1,417.54 +3.19% 5,252,127
26-10-29 US$1,373.70 +6.63% 4,373,521
26-10-28 US$1,288.30 +0.50% 2,061,427
26-10-27 US$1,281.91 +0.22% 1,849,712
26-10-26 US$1,279.14 +0.45% 2,106,876
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Eli Lilly and Company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,417.54USD
Average target price
1,403.64USD
Spread / Average Target
-0.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eli Lilly and Company